Related Experiment Video
Updated: Oct 16, 2025
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.4K
Anastrozole Regulates Fatty Acid Synthase in Breast Cancer
Junmei Cairns1, James N Ingle2, Krishna R Kalari3
1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
Molecular Cancer Therapeutics
|October 20, 2021
Summary
Anastrozole, unlike other drugs, maintains fatty acid synthase (FASN) protein levels, promoting breast cancer growth. Targeting this pathway may overcome endocrine resistance in breast cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Previous studies linked anastrozole, but not exemestane or letrozole, to breast cancer risk based on estrogen levels.
- Anastrozole is a ligand for estrogen receptor α, suggesting distinct mechanisms of action.
Purpose of the Study:
- To elucidate the novel mechanism by which anastrozole promotes breast cancer cell growth.
- To identify the role of fatty acid synthase (FASN) in anastrozole-mediated endocrine resistance.
Main Methods:
- Investigated the effect of anastrozole on FASN protein levels and degradation pathways.
- Examined the expression of GET4, BAG6 complex activity, and RNF126 in relation to FASN.
- Analyzed the association between FASN levels and patient outcomes in breast cancer treated with different endocrine therapies.
Main Results:
- Anastrozole treatment maintains FASN protein levels by inhibiting ubiquitin-mediated degradation.
- Anastrozole decreases GET4 expression, reducing BAG6 activity and preventing FASN degradation by RNF126.
- Elevated FASN levels correlate with poor outcomes specifically in anastrozole-treated breast cancer patients.
- Inhibition of FASN leads to regression of breast cancer cell growth.
Conclusions:
- Anastrozole promotes breast cancer growth by stabilizing FASN protein levels through a novel molecular pathway.
- The anastrozole-FASN signaling axis represents a potential therapeutic target for endocrine-resistant breast cancer.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:28Overview of Fatty Acid Metabolism
32.2K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
32.2K